Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohnʼs disease

Abstract

Our study confirms that a large proportion of endoscopic recurrences occur within 3 months of resection in Crohn's disease. There was a slight trend towards greater efficacy of Claversal; it could be worthwhile trying higher dosages and/or 5-ASA compounds with different intestinal release profiles.